Ecomax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
May 15, 2024 at 06:08 am EDT
Share
Ecomax, Inc. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported sales was USD 0.108824 million compared to USD 0.096221 million a year ago. Net loss was USD 0.018529 million compared to USD 0.020292 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
For the nine months, sales was USD 0.471 million compared to USD 0.096221 million a year ago. Net loss was USD 0.041793 million compared to USD 0.080114 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.
Ecomax, Inc. is engaged in selling and distributing Rocitin NMN products to customers in the Territory. Rocitin NMN is a nutritional supplement manufactured by Pharmazeutische Fabrik Evers GmbH & Co. KG, a German company. Each bottle contains 60 capsules, 10080 mg of NMN. NMN, as β-Nicotinamide Mononucleotide exists in some fruits, vegetables, and poultry. It is a molecule naturally occurring in all life forms and can be transformed into a significant coenzyme NAD+ within cells, which is important to human metabolism. Its research, including Nicotinamide mononucleotide (NMN) as an anti-aging health product has shown that NAD+ levels in the body will decrease with age, and that exogenous supplementation of NMN enhances NAD+ levels and thus the function of human cells. In addition, NMN also helps to repair broken DNA, regulate the stability of DNA and cell death, and improve neurodegenerative and metabolic conditions.
ECOMAX, INC. 
